By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health on Thursday began offering a much ...

Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal" ...

By Maggie Fick and Bhanvi Satija LONDON, Feb 6 (Reuters) - Hims & Hers' gambit to sell a $49 compounded version of Novo ...

Hims & Hers will sell a compounded version of the new Wegovy pill for a fraction of the price, claiming a legal workaround to ...

Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 ...

Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a ...

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

Hims & Hers (HIMS) stock jumps as the company plans to launch cheaper compounded versions of Novo Nodisk's (NVO) Wegovy pill.

The off-brand version comes just weeks after Novo Nordisk launched its reformulation of the blockbuster medication.

Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking ...